Somewhere along the way, we’ve confused newness with progress, launches with breakthroughs, and virality with impact. In an industry built on a nonstop launch cycle, we’ve lowered the bar for what we call innovation. When innovation becomes just another marketing term, it stops meaning anything. Adding an ingredient to a formulation because it has buzz doesn’t make the product innovative unless it improves performance. The answer shouldn’t be another format, texture, or delivery system masquerading as something new. It should expand what’s possible by applying advanced science to challenges beauty hasn’t yet been able to solve. I believe that comes down to four principles:
Innovation must break new ground or raise the bar. Otherwise, don’t call it innovation. Innovation creates new territory; it doesn’t simply compete for share within the existing landscape or make a product marginally better by optimizing a formulation. The question shouldn’t be “What should we launch next?” but rather “What can science make possible that wasn’t possible before?” That could mean discovering a new molecule or biological mechanism that targets a consumer problem or emerging need and creating a capability or solution that didn’t exist before.
Sustainability is not innovation. Superior sourcing or more thoughtful packaging matter, but they shouldn’t be confused with innovation. Likewise, a proprietary molecule isn’t inherently better because it is proprietary. Can we make products for specific skin types, geographies, ages, or stages of life? Can we solve needs that existing ingredient libraries cannot? These are the kinds of questions that will define the next era of beauty. Innovation has been incremental for too long, but that is changing as more brands bring PhD scientists into the business, and science moves closer to the center of product development.
Find the need before the fix.
Beauty traditionally begins with formulation, but today innovation increasingly happens much further upstream. The biggest opportunity is to start with the problem, understand the underlying biological mechanism, and then determine what could solve it. Now, we are moving from product development driven by retail calendars, shelf space, and market share to innovation driven by what consumers actually need.
Longevity is a clear example. Research into cellular senescence, mitochondrial function, and cellular repair is shifting the focus from treating the signs of aging to influencing the underlying biology. That is a fundamentally different starting point for innovation. But much of what reaches the shelf still reflects the limits of existing ingredient portfolios and contract manufacturing rather than the limits of science. Brands cannot formulate with breakthroughs they cannot access. Retailers have a role too: When will scientific expertise sit alongside merchandising expertise in deciding which products deserve shelf space?
AI is accessible. The advantage is what you build with it.
We are entering a period in which data is an innovation asset rather than a marketing asset. AI alone is not an advantage. With the commoditization of AI, the technology itself will no longer be a differentiator. Soon, every brand will have access to AI, better consumer insights, and tools that can predict what consumers want next. Real innovation requires new science. The advantage comes from combining AI with reliable, differentiated data and scientific expertise and applying all three toward a specific problem. The result is not simply faster R&D. It’s a model of discovery in which data generates proprietary knowledge and IP that creates first-of-their-kind products. The winners will be the companies that can translate AI, science, and consumer insight into products that could not have existed before.
Innovation doesn’t end in the lab.
Beauty’s innovation model is changing. As science advances, the gap between discovery and commercialization widens. Discovery is only one part of the equation. Innovation also involves figuring out what it takes to get that discovery out of the lab and into consumers’ hands. A breakthrough has to be formulated, manufactured reliably, scaled economically, and integrated into products that brands can bring to market. That requires the path to market to be baked in from the start, not handed off once the science is done.
The last biotech investment cycle exposed the limits of horizontal integration. Significant capital flowed into technologies that never reached the market. A new wave of vertical companies is working directly with brand builders to take science from discovery to the consumer.
Innovation should create an advantage that is difficult to replicate. The goal isn’t simply to get to market first. It’s to own something others can’t easily replicate. In a market where products can be duped at record speed, the most enduring differentiation will come from proprietary science that expands what beauty can do.
But none of it means anything if the consumer doesn’t understand why it matters. Beauty has to raise the standard of proof. Consumers should be able to tell the difference between a new marketing story and a genuine breakthrough. As beauty embraces more advanced science, the standard for proving that it works should rise with it—perhaps including the regulatory standard. If a brand claims innovation from a peptide, exosome, or other advanced technology, should it have to demonstrate that the technology survives formulation, remains effective throughout its shelf life, and delivers the claimed benefit? Real innovation should welcome that scrutiny. If it works, prove it.